stockrowViridian Therapeutics, Inc.
VRDN Healthcare Biotechnology
Viridian Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $70.8 million, up 23,359.9% from fiscal 2024.
- Revenue
- −63.5%
- EPS
- −5.00%
- Free cash flow
- −9.92%
- Total debt
- +1,064.9%
Quarter to September 2026, against a year earlier
Follow VRDN
Alert me
Viridian Therapeutics, Inc. (VRDN) Return on assets
Viridian Therapeutics, Inc.'s return on assets over the twelve months to 30 September 2026 was −56.5%, down 14.8 percentage points from fiscal 2025 (−41.7%). Over the past ten years it has ranged from −137.1% (fiscal 2020) to −40.7% (fiscal 2022); the current reading is higher than 91% of that period. That is below the Biotechnology industry median of −45.6% and below the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | −41.7% | 2.06 |
| FY2024 | −43.8% | 7.58 |
| FY2023 | −51.4% | (10.71) |
| FY2022 | −40.7% | 6.76 |
| FY2021 | −47.4% | 89.67 |
| FY2020 | −137.1% | (50.22) |
| FY2019 | −86.9% | (31.73) |
| FY2018 | −55.1% | 13.52 |
| FY2017 | −68.7% | 23.33 |
| FY2016 | −92.0% | 15.94 |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| TLX Telix Pharmaceuticals Limited compare | 0.00% |
| ELVN Enliven Therapeutics, Inc. compare | −15.0% |
| DNLI Denali Therapeutics Inc. compare | −27.2% |
| IDYA IDEAYA Biosciences, Inc. compare | −35.0% |
| CELC Celcuity, Inc. compare | −44.8% |
| VRDN Viridian Therapeutics, Inc. | −56.5% |
| DYN Dyne Therapeutics, Inc. compare | −60.3% |
| VKTX Viking Therapeutics, Inc. compare | −73.1% |
| TARS Tarsus Pharmaceuticals, Inc. compare | −135.0% |
| Biotechnology industry median | −45.6% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on VRDN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement